FDA — authorised 7 August 2024
- Application: BLA761312
- Marketing authorisation holder: CITIUS PHARMS
- Local brand name: LYMPHIR
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 LYMPHIR in United States
FDA authorised LYMPHIR on 7 August 2024
Marketing authorisations
FDA
- Status: approved
LYMPHIR in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is LYMPHIR approved in United States?
Yes. FDA authorised it on 7 August 2024; FDA has authorised it.
Who is the marketing authorisation holder for LYMPHIR in United States?
CITIUS PHARMS holds the US marketing authorisation.